

# Pneumocystis Pneumonia: An Update

Sureeporn Sritangratanakul MD\*,  
Surang Nuchprayoon MD, MPH, PhD\*, Issarang Nuchprayoon MD, PhD\*\*

\* Department of Parasitology, Faculty of Medicine, Chulalongkorn University

\*\* Department of Pediatrics, Faculty of Medicine, Chulalongkorn University

---

*Pneumocystis pneumonia is a major cause of illness and death in immunocompromised hosts. The numbers of pneumocystis pneumonia cases in Thailand have increased each year from 1992 to 2000 and peaked in 2000 at 6,255 cases. The microbe that causes pneumocystis pneumonia in humans is called *Pneumocystis jirovecii*. *Pneumocystis* sp. was discovered nearly a century ago, but the knowledge of *Pneumocystis* sp. remained poorly understood, until the molecular biology techniques help scientists verify its fungus nature. In the past, *Pneumocystis* sp. was misclassified as protozoan due to its morphologic features. Later, it was reclassified as fungus due to DNA analysis. Cotrimaxazole, the combination of trimethoprim-sulfamethoxazole, is the drug of choice for treatment and prophylaxis of pneumocystis pneumonia. However, increasing evidence of mutations in the enzyme dihydropteroate synthase (DHPS), the target of sulfa drugs represent emergence of sulfa resistance.*

**Keywords :** *Pneumocystis pneumonia, Life-cycle, Clinical, Treatment, Prophylaxis*

**J Med Assoc Thai 2004; 87 (Suppl 2): S309-17**

**e-Journal:** <http://www.medassocthai.org/journal>

---

*Pneumocystis* sp. is an atypical fungus that remains a serious cause of sickness and death in immunocompromised patients. The *Pneumocystis* organism was first identified as a protozoan nearly 100 years ago by Carlos Chagas <sup>(1)</sup>. Based on advanced molecular studies, *Pneumocystis* has been reclassified as a fungus by using DNA sequence analysis of srDNA genes <sup>(2,3)</sup>. *Pneumocystis* infection is host species specific <sup>(4)</sup>. Human specific *Pneumocystis* has been recently renamed *Pneumocystis jirovecii* <sup>(5)</sup>. The prevalence of pneumocystis pneumonia has increased in AIDS patients especially in those who do not receive adequate antiretroviral drug. Trimethoprim-sulfamethoxazole remains the first-line drug for treatment and prophylaxis of pneumocystis pneumonia. However, accumulating evidence has demonstrated that the gene mutations in enzyme dihydropteroate synthase (DHPS), the target of sulfa drugs, appear to represent emerging resistance in pneumocystis pneumonia <sup>(6)</sup>.

## **Epidemiology of *Pneumocystis* organism**

Historically, *Pneumocystis carinii* was first identified in the early 1900s in trypanosome-infected lungs of animals by Carlos Chagas, who believed it was a form of trypanosome <sup>(1)</sup>. Subsequently, Antoni Carinii identified the same organism in infected rat lung <sup>(7)</sup>.


---

Correspondence to : Nuchprayoon S. Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Several years later, Delanoes recognized that Chagas and Carinii had identified a new genus and it was named *Pneumocystis carinii* in honor of Carinii <sup>(8)</sup>. In the 1930s and 1940s, pneumocystis pneumonia was associated with premature and malnourished infants in Europe and subsequently with patients undergoing organ transplantation, or receiving chemotherapy for the treatment of malignant disease <sup>(9)</sup>. Recently, the highest incidence of pneumocystis pneumonia is in AIDS patients and the number of recognized cases has increased since 1993.

## **Cases of *Pneumocystis* Pneumonia in Thailand**

Before 1992, there were fewer than 100 cases per year of pneumocystis pneumonia in Thailand. After 1993, there was a marked increase in the incidence of cases reported to the Thai Ministry of Public Health that peaked in 2000 at 6,255 cases per year (Fig. 1) <sup>(10)</sup>. In most developed countries, pneumocystis pneumonia has been the most common AIDS-defining infections since the beginning of the epidemic, accounting for nearly 67% of all initial AIDS diagnosis <sup>(11)</sup>. However, in Thailand, pneumocystis pneumonia was reported in 19.8% of patients with AIDS because many of these diagnoses were made on clinical grounds alone, these data may not accurately reflect the true incidence of pneumocystis pneumonia <sup>(12)</sup>. In 2002, there was a minimal decline in the number of pneumocystis pneumonia cases that may be due to the use of pneumocystis pneumonia prophylaxis and antiretroviral therapy. In



**Fig. 1** Cases of pneumocystis pneumonia reported to the Thai Ministry of Public Health, 1991-2002

developing countries, primary prophylaxis for opportunistic infections such as pneumocystis pneumonia, toxoplasmosis, cytomegalovirus (CMV) infection and Mycobacterium Avium Complex (MAC) infection are recommended and considered as a standard of care<sup>(13)</sup>. However, these approaches are compromised by limited resources and should be implemented differently in each country. In Thailand, the treatment and prevention of opportunistic infections (OI) are strongly advocated by Thai policy because it is considered to be cheaper and more affordable than antiretroviral drugs due to the high cost<sup>(14)</sup>. Primary prophylaxis of pneumocystis pneumonia, using a combination of trimethoprim-sulfamethoxazole as a first-line drug, is recommended as standard care, because it is the most cost-effective and widely implemented regimen for HIV cases in Thailand<sup>(13)</sup>.

#### **Advances in understanding the biology of *Pneumocystis* organisms**


The knowledge on biology of *Pneumocystis* sp. has been investigated for many decades. *Pneumocystis* organisms were first identified as a protozoan because of the morphologic features<sup>(8)</sup>. Based on advanced molecular studies, *Pneumocystis* sp. has been reclassified as a fungus by analysis of the srRNA subunit<sup>(15,16)</sup>. *Pneumocystis* sp. was originally thought to be only one strain that was capable of infecting many different mammalian host species. However, advanced studies have shown that there are many different types of *Pneumocystis* organisms, each of which is restricted to infecting a single host species<sup>(17-19)</sup>.

*Pneumocystis* sp. that infects humans, which is *P. carinii* f. sp. *hominis*, cannot infect mice, rats, or even monkeys. This organism was recently renamed *P. jirovecii*, in honor of the Czech parasitologist Otto Jirovecii, according to the requirements of the International Code of Botanical Nomenclature (ICBN)<sup>(20,21)</sup>. *Pneumocystis carinii* was retained for one of the two *Pneumocystis* species inhabiting rats<sup>(20,21)</sup>. Therefore, *Pneumocystis carinii* pneumonia (PCP) is referred to pneumocystis pneumonia because of taking the species name out of the disease name. *P. carinii* genome project has identified about 4,000 genes in rat *P. carinii*. The sequencing of cDNA expression has revealed about 2,000 genes that share homology with known sequences 1,412 of which were fungi (Table 1). *Pneumocystis* is now classified as an Archiascomycetous fungus<sup>(22,23)</sup>.

#### **Life Cycle and Morphology**

The life cycle of *Pneumocystis* is still not clearly understood because these organisms cannot be cultured. This organism was studied on microscopic observation in mammalian lungs and in vitro culture. The various stages of the organisms include ascospores, pre-asci, asci and trophic forms are seen in alveolar spaces in host lung cells.

The *Pneumocystis* life cycle are seen as starting with the release of ascospores from the ascus (Fig. 2). These ascospores are haploid and smaller than mature trophic forms. They have an amoeboid form, several small knob-like projections extending outward, which were misunderstood to be a protozoan. The released scoopers conjugate in pairs to form the trophic forms. The electron microscope demonstrates that the



**Fig. 2** Proposed of *Pneumocystis* Life Cycle

**Table 1.** Distinguish *Pneumocystis sp.* between fungi and protozoan features

<i>Protozoan features</i>	<i>Fungus features</i>
1. Strong similarities in microbe morphology and host pathology	1. The sequencing of cDNA expression about 2,000 genes, which sharing homology with known sequences 1,412 of which were fungi
2. Absence of some phenotypic features typical of fungi	2. Lacking in ergosterol
3. Presence of morphologic features typical of protozoan	3. Absence of structure for motility
4. Ineffectiveness of antifungal drugs	4. Absence of structure for phagocytic
5. Effectiveness of drugs generally used to treat protozoa	5. Very difficult to culture.
6. Life cycle similarities to protozoan	6. Similarities in fungi cell wall


nucleus of the trophic is much larger than that of the ascospore forms because it is now diploid. It supports the hypothesis of conjugation of encysted organisms<sup>(24)</sup>. At this stage, an organelle conducts the alignment of homologous chromosomes, which suggesting the presence of meiosis replication<sup>(25)</sup>. Mitotic divisions was followed after meiosis division in late pre-asci resulting in the formation ultimately of eight nuclei. The body of the ascus produces the nucleated ascospores.

*Pneumocystis* organisms adhere to each other and to type 1 pneumocytes, but not to type 2 pneumocytes<sup>(26)</sup>. The adherence mechanism is still unknown. *P. carinii* is found tightly adhere with alveolar and adjacent trophozoite cell membrane<sup>(27)</sup>. Numerous glycoproteins, which function as adhesions, have been identified on its surface<sup>(28,29)</sup>. One glycoprotein, gp120, has been demonstrated to bind fibronectin and may function in the formation of a fibronectin bridge between *P. carinii* and host epithelium<sup>(30)</sup>. However, the significance of this attachment in pathogenesis is still not fully understood.


The cyst of *P. carinii* is a spherical to ovoid structure 4 to 6  $\mu$ m in diameter. It has a three-layered cell wall and usually contains up to eight pleomorphic sporozoites (Fig. 3, 4). The trophozoite are 1-5  $\mu$ m long, uninucleated, ameboid structures with a double-layered wall. Precysts are approximately 5  $\mu$ m. long, oval, smooth, and have a thick cell wall<sup>(31)</sup>. The *Pneumocystis* organisms are seen as foamy intra-alveolar exudates the nucleus of which has faint basophilic dots. The methenamine silver stain can stain the asci only, which comprises about 10-30% of the organisms. The Diff-Quik (Hemacolor) stain visualized all structures of the organism except the ascus wall. A research suggests Diff-Quik is superior to the silver stain because the organism can be identified easier<sup>(32)</sup>.

#### **Transmission of *Pneumocystis sp***

Mode of transmission in humans is unknown, though an airborne route is likely important through a



**Fig. 3** Giemsa stain of the fluid sputum materials, observed at 1000 x magnification, shows cluster of *Pneumocystis* trophozoites and intracystic bodies of *Pneumocystis*, although the cyst walls do not stain



**Fig. 4** A mature cyst containing 8 intracystic bodies is seen in Giemsa stained smear, observed at 1000 x magnification

series of animal experiments. This study demonstrated transmission from infected rats to susceptible immunocompromised rats in close contact<sup>(33)</sup>. For a decade, it

was thought that pneumocystis pneumonia resulted from reactivation of latent infection<sup>(34-37)</sup>. The organism remains latent within the host, subsequently, if the host's immune system fails, the latent *P. carinii* can reactivate and cause disease. A research found that healthy children with no detectable anti-antibodies at birth or in the first 3 months of life began to demonstrate a titer at 7 months of age<sup>(33)</sup>. In the present study, 83% of healthy children had at least 1:16 by the age of 4 years. This studies may support the hypothesis that *P. carinii* can exist in its host for long periods of time with asymptomatic of pneumocystis pneumonia. Several years later, there was accumulating evidence against the theory of reactivation of latent infection. Recent studies using sensitive and specific molecular techniques did not find *P. carinii* in healthy immunocompetent hosts<sup>(38,39)</sup>. A experiment did not find *P. carinii* in immunocompetent hosts after treatment of pneumocystis pneumonia and the presence of genotype switching in repeat episodes of pneumocystis pneumonia, and geographic variability in the disease which did not support the reactivation of latent infection theory<sup>(40)</sup>. Several studies have reported that different *P. carinii* genotype are present during repeat episodes of *P. carinii* in the same patient<sup>(41,42)</sup>. It cannot explain following reactivation of the latent theory because if this theory is true the genotype of *P. carinii* should be constant. Another argument against the latency hypothesis from studies of the geographic distribution of *Pneumocystis* strains and infection with *Pneumocystis*. Several studies demonstrated that frequencies of *P. carinii* genotypes vary in different cities and countries<sup>(43,44)</sup> and the strains reflect the patient's place of infection. Moreover, the strains better reflect the patient's place of infection rather than the place of birth, implying that infection has been recently acquired<sup>(44)</sup>. Subsequently, the latency theory cannot explain some situations. The possibility that *P. carinii* can be transmitted from person to person. The studies reported a group of pneumocystis pneumonia patients, with malignancies had contact with each other within a hospital. It was suggested that person to person transmission of pneumocystis pneumonia may occur from an infected susceptible immunocompromised patient in close contact<sup>(45,46)</sup>. Recently, evidence is the most likely mode of acquiring new infection from person to person. However, significant evidence of transmission of pneumocystis pneumonia does not have at this period.

#### **Clinical Presentation of Pneumocystis Pneumonia**

*Pneumocystis sp.* produces disease when

alveoli become diffusely packed with organisms, which these organisms are usually accompanied by inflammatory cell interstitial reaction. Pneumocystis pneumonia results in a lung that is stiffened, which loading breathing capacity, and that exchanges oxygen poorly, which results in hypoxaemia. If the disease progresses, it becomes respiratory failure<sup>(47)</sup>. Pneumocystis pneumonia is often infected in immunocompromised hosts. The dominant symptoms of pneumocystis pneumonia are fever, progressive dyspnea and nonproductive cough<sup>(48)</sup>. The patient initially has dyspnea on exertion, then later occurs at rest, although orthopnea and nocturnal dyspnea are not features of this disease. The non-productive cough is irritating. On physical examination, tachypnea is characteristic (respiratory rate over 20 times per minute) and fever over 38 °C occurs. The chest is generally clear on auscultation, occasional crepitation being audible. Pneumocystis pneumonia does not involve the pleura or bronchi. Therefore, manifestation of pneumocystis pneumonia are not present as pleuritic chest pain, wheeze or productive cough. AIDS patients who have pneumocystis pneumonia typically present with more insidious onset of respiratory insufficiency, having a median duration about 3-4 weeks, than non AIDS patients<sup>(49)</sup>.

#### **Diagnosis of Pneumocystis Pneumonia**

Diagnosis of pneumocystis pneumonia was based on history, physical examination and confirmed by investigation. The chest radiograph characteristically demonstrates bilateral perihilar interstitial infiltrates, which progresses to become more homogeneous and diffuse (Fig. 5). Although in 10% or more of pneumocystis pneumonia cases, the chest radiograph may be entirely normal, and computer tomography scan of the chest may demonstrate extensive ground-glass attenuation<sup>(50)</sup>. AIDS patients, who have pneumocystis pneumonia, usually present with mild symptoms, modest hypoxaemia and normal chest radiograph<sup>(51)</sup>.

In the past, diagnosis was based on the demonstration of the organisms in material from the lungs or in lung tissue, in suspected cases of pneumocystis pneumonia because *Pneumocystis sp.* cannot be cultured. Sputum induction and bronchoscopy are effective techniques for obtaining specimens, which are used for diagnosis of pneumocystis pneumonia. Thus, the initial procedure for diagnosis of pneumocystis pneumonia should be sputum induction<sup>(52)</sup>, and if that smear is negative, to proceed to bronchoalveolar lavage. Although prophylaxis of pneumocystis pneu-




**Fig. 5** The posteroanterior chest radiograph of a 48-year-old patient with pneumocystis pneumonia demonstrating bilateral perihilar interstitial infiltrates

monia, by aerosolized pentamidine, which reduced organisms in induced sputum specimens, the yield appears to be high enough for the diagnosis of pneumocystis pneumonia in AIDS patients because AIDS patients have more organisms than other immunocompromised patients<sup>(53)</sup>.


Cyst form of *Pneumocystis* organism can be detected by Gomori methenamine silver (GMS) (Fig. 6, 7), Gram-Weigert, or toluidine-blue O stains (Fig. 8, 9). Trophic form can be stained with modified Papanicolaou, Wright-Giemsa, or Gram-Weigert stain. Although *Pneumocystis* organism was seen in cyst form, sporozoite form and trophic form with giemsa stains (Fig. 3, 4), this technique is not sensitive because the contrast of this organism against host cells was not outstanding in these stains<sup>(54)</sup> (Fig. 6). Calcofluor white chemofluorescent stain is a simple, rapid and inexpensive method for detection of *Pneumocystis* organisms<sup>(55)</sup>. The application of a mouse monoclonal antibody (2G2), by indirect immunofluorescent assay is sensitive and specific<sup>(56)</sup>. It can detect both cysts and trophozoite. Physicians who work with AIDS patients need a sensitive, reliable, and noninvasive tool for early detection and diagnosis of pneumonia. Polymerase chain reaction (PCR) that amplify *P. carinii* DNA sequence from bronchoalveolar lavage fluid and induced sputum, are more sensitive and specific than microscopic stain<sup>(57)</sup>. PCR for detection of *P. carinii* DNA in serologic assays is not of value for diagnosis<sup>(58)</sup>.

### Prophylaxis and Treatment

Mild to moderate symptoms of pneumocystis pneumonia can be treated as out-patients by using oral therapy and close follow up. This decision is based




**Fig. 6** The Gomori methenamine silver stained-smears, observed at 400 x magnification, shows clusters of *Pneumocystis* cyst are black round to cup-shaped



**Fig. 7** Cluster of *Pneumocystis* cyst found in Gomori methenamine silver stained-smears, observed at 1,000 x magnification


on the clinical status of the patient including the degree of dyspnea, cough, fever, and oxygen saturation, as well as the ability of toleration and compliance with oral therapy<sup>(59)</sup>. A patient with significant hypoxaemia should be hospitalized for intravenous therapy. Respiratory failure patient should be admitted to the ICU<sup>(60)</sup>. Cotrimoxazole, the combination of sulphamethoxazole (SMX) with trimethoprim (TMP), is the first-line drug for the treatment of pneumocystis pneumonia (Table 2). A significant number of patients cannot tolerate the adverse effects of Cotrimoxazole. Alternative therapeutic agents such as atovaquone, trimethoprim plus dapsone, pentamidine, and clindamycin plus prima-



**Fig. 8** The toluidine-blue O stained smears, observed at 400 x magnification, show purplish round cyst against the pale green background

quine are also used (Table 2). Corticosteroids should be given to AIDS patients with pneumocystis pneumonia who have hypoxia (air  $\text{PaO}_2 < 70$  mmHg within 72 hours of initial therapy while breathing room air) <sup>(61)</sup>.

Cotrimoxazole (SMX-TMP) is also a first-line drug on the prophylaxis of pneumocystis pneumonia, for patients with no history of sulfa allergy (Table 3). Alternative therapeutic agents are Atovaquone, Dapsone, Dapsone plus pyrimethamine (Table 3). Primary prophylaxis should start when CD4+ count is less than 200 cells/millimeter, and when AIDS patients increase CD4+ could be discontinued for 3 months and reintroduced again when CD4+ count falls less than 200 cells/millimeter, or a history of oropharyngeal candidiasis in AIDS patients (including pregnant women) <sup>(62)</sup>. Life-long second prophylaxis is recommended for patients who recovered from an episode of pneumocystis pneumonia. Patients receiving immunosuppressive medications or having an underlying acquired or inherited



**Fig. 9** Cluster of Pneumocystis cysts appear as characteristic disc-like structure, in toluidine-blue O stained smears, observed at 1,000 x magnification

immunodeficiency without AIDS should receive prophylaxis against pneumocystis pneumonia <sup>(63)</sup>. Patients who were treated with up to 25 mg. of MTX per week should receive prophylaxis and if they did not develop severe myelosuppression but they should have close monitoring with CBC and liver function test <sup>(64)</sup> (Table 3).

### ***Emerging of Drug Resistant Strains of Pneumocystis jirovecii***

The enzyme dihydropteroate synthase (DHPS) is the target of sulpha and sulphone drugs in the folic acid pathway. Dihydropteroate synthase (DHPS) catalyses the condensation of *p*-aminobenzoic acid and 6-hydroxymethyl-7, 8-dihydropterin pyrophosphate to form dihydropteroate. DHPS in *P. carinii* is part of a trifunctional protein with two other enzymes

**Table 2.** Drugs for treatment of pneumocystis pneumonia

Drug	Route	Dose
<u>Drug of choice</u>		
-Trimethoprim-sulfamethoxazole	oral	TMP 15-20 mg/kg/day plus SMX 75-100 mg/kg/day, twice a day
	intravenous	TMP 5 mg/kg plus SMX 25 mg/kg every 8 hours
<u>Alternatives</u>		
-Atovaquone	oral	750 mg twice a day
-Trimethoprim plus dapsone	oral	TMP 5 mg/kg every 8 hours plus dapsone 100 mg daily 4 mg/kg daily
-Pentamidine	intravenous	300-450 mg every 6 hours
-Clindamycin plus primaquine	oral, intravenous	15-30 mg daily
<u>Adjunctive therapy</u>		
-Prednisolone (if room air $\text{PaO}_2 < 70$ mmHg within 72 hours of initialing therapy)	oral	40 mg every 12 hours for 5 days, then 40 mg daily for 5 days, then 20 mg daily for 11 days
	oral, intravenous	

**Table 3.** Drugs for prophylaxis against pneumocystis pneumonia

Drug	Route	Dose
<b>Drug of choice</b>		
-Trimethoprim-sulfamethoxazole	oral	1 double-strength tablet daily or 1 single-strength tablet daily
<b>Alternatives</b>		
-Dapsone	oral	50 mg twice a day or 100 mg daily
-Dapsone plus pyrimethamine plus leucovorin	oral	50 mg daily 50 mg weekly 25 mg weekly
-Dapsone plus pyrimethamine plus leucovorin	oral	200 mg weekly 75 mg weekly 25 mg weekly
-Pentamidine	aerosol	300 mg/kg monthly
-Atovaquone	oral	1,500 mg daily

in folic-acid biosynthesis pathway<sup>(65)</sup>. Mutation of the gene that encodes dihydropteroate synthase may cause resistance to sulpha agents by decreasing the affinity for sulpha and sulphone drugs. In addition, the mutation of DHPS has been observed in association with the failure of sulpha treatment<sup>(66)</sup> and prophylaxis and prognosis<sup>(65)</sup>, suggesting that emergence of sulpha drug resistance. Recently, many studies have shown that point mutations in the dihydropteroate synthase (DHPS) gene of human-derived *P. carinii* are related to exposure to sulpha drugs. Mutation of the gene that encodes dihydropteroate synthase may cause resistance to sulpha agents by decreasing the affinity for sulpha and sulphone drugs and possibly represent emergence of sulfa resistance.

#### ***Pneumocystis* genome projects**

International *Pneumocystis* genome project purpose for determining the complete genome sequence of the *P. carinii* and *P. jirovecii*. The genome project will help us to understand more about these organisms. Researchers will discover new knowledge new therapeutic target, evolution differences among the species, which may contribute to the identification of new drug target for prevention and treatment. The *Pneumocystis* genome project plans to finish by early 2005<sup>(67)</sup>.

#### **Conclusion**

*Pneumocystis* pneumonia is one of the most common opportunistic infections especially in patients with AIDS. Although *Pneumocystis* *sp.* cannot be cultured, molecular and immunologic approaches help to discover facts of these organisms. *Pneumocystis* *sp.* is a host-specific organism. The organism that causes human PCP is now named *Pneumocystis jirovecii*, which

is now classified as an Archiascomycetous fungus. Diagnosis has been improved by the development of organism-specific monoclonal antibodies and more by polymerase chain reaction. Prophylaxis and treatment failure have been reported for trimethoprim-sulfamethoxazole, considered due to point mutations in dihydropteroate synthase (DHPS). Sequencing of the genome of *Pneumocystis* *sp.* is going to help us to understand more and more about these organisms.

#### **Acknowledgements**

The authors wish to thank Associate professor doctor Narin Hiransuthikul, Department of Preventive and social Medicine Faculty of Medicine, Chulalongkorn University who gived us many suggestions. We are also most gratefully to Ms. Jaruratt Prownebon for the help of taking photograph, the medical technologist in department of Parasitology, Chulalongkorn University.

#### **References**

1. Chagas C. Nova tripanozomíaze humana: estudo sobre a morfologia e o evolutivo do *Schizotrypanum cruzi* n.gen., n. sp., agente etiológico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1909; 1: 159-218.
2. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows *Pneumocystis carinii* to be a member of the fungi. Nature (London) 1988; 334: 519-22.
3. Stringer SL, Stringer JR, Blas MA, et al. *Pneumocystis carinii*: sequence from ribosome RNA implies a clear relationship with fungi. Exp Parasitol 1989; 68: 450-61.
4. paper 1.41 Gigliotti F, Harmsen AG, Haidaris CG, Haidaris PJ. *Pneumocystis carinii* is not universally transmissible between mammalian species. Infect Immun 1993; 61: 2886-90.
5. James RS, Charles BB, Robert FM, Ann EW. A new name (*Pneumocystis jirovecii*) for *Pneumocystis* from humans. Emerg Infect Dis 2002; 8: 891-6.
6. Thomas RN, Charles BB, Laurence H, Carlos dR, Sherline L, Norman JP, Jane LC, Thuy L, Allen H, David R. Effect of mutations in *Pneumocystis carinii* dihydropteroate synthase gene on outcome of *P. carinii* pneumonia in patients with HIV-1. Lancet 2001; 358: 545-9.
7. Carinii A. Formas de eschizogonia do *Trypanozoma Lewisii*. *Comunica-zones des Sociedade de Medicina*, Sao Paulo 1910: 204.
8. Delanoe P, Delanoe M. De la rareté de *Pneumocystis carinii* chez les cobayes de la région de Paris, absence de kystes chez d'autres animaux: lapin, grenouille, 3 anguilles. Bulletin de la Société de Pathologies Exotiques et de ses Filiales, 7, 271.
9. Vanek J, Jirovek O. Parasitare Pneumonia "Interstitielle" Plasmazellenpneumoniae der Frühgeborenen, verursacht durch *Pneumocystis carinii*. Zentralbl Bakteriell 1952; 158: 120-7.
10. The division of Epidemiology of the Thai Ministry of Public Health.
11. Chariyaletsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with Acquired Immunodeficiency Syndrome in Thailand

- 1994-1998 Regional variation and temporal trends. Clin Infect Dis 2001; 32: 955-62.
12. Centers for Disease Control and Prevention. USPHA/IDSA guidelines for the prevention of opportunistic infections in person infected with HIV. MMWR 1999; 48: 1-66.
13. Kiat R, Praphan P. Update on HIV/AIDS in Thailand. J Med Assoc Thai 2001; 84: S1-16.
14. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows *Pneumocystis carinii* to be a member of the fungi. Nature 1988; 334: 519-22.
15. Stringer SL, Stringer JR, Blas MA, et al. *Pneumocystis carinii* sequence from ribosome RNA implies a clear relationship with fungi. Exp Parasitol 1989; 68: 450-61.
16. Kovacs JA, Halpern JL, Lundgren B, et al. Monoclonal antibodies *Pneumocystis carinii*. J Infect Dis 1989; 159: 60-70.
17. Stringer JR. *Pneumocystis carinii*: what is it, exactly? Clin Microbiol Rev 1996; 9: 489-98.
18. Ann EW. *Pneumocystis carinii*. British Medical Bulletin 2002; 61: 175-88.
19. The *Pneumocystis* Workshop. Revised nomenclature for *Pneumocystis carinii*. J Eukaryote Microbiol 1994; 41: 121-2.
20. Hawksworth DL. International Code of Botanical Nomenclature. Koeltz Scientific Books, Konigstein, Germany 2000.
21. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows *Pneumocystis carinii* to be a member of the fungi. Nature (London) 1988; 334: 519-22.
22. Stringer SL, Stringer JR, Blas MA, et al. *Pneumocystis carinii* sequence from ribosomal RNA implies a clear relationship with fungi. Exp Parasitol 1989; 68: 450-61.
23. Itatani CA. Ultrastructural morphology of intermediate forms suggestive of conjugation in the life cycle of *Pneumocystis carinii*. J Parasitol 1996; 82: 163-71.
24. Matsumoto Y, Yoshida Y. Sporogony in *Pneumocystis carinii*: synaptonemal complexes and meiotic nuclear divisions observed in precysts. J Protozool 1984; 31: 420-8.
25. Sidhu GS. Ultrastructural aspects of AIDS: neoplasms and infections. Pathology of AIDS and Other Manifestations of HIV Infection. New York: Igaku-Shoin; 1990: 271-312.
26. Long EG, Smith JS, Meier JL. Attachment of *Pneumocystis carinii* to rat pneumocytes. Lab Invest 1986; 54: 609-15.
27. Cushion MT, DeStefano JA, Walzer PD. *Pneumocystis carinii*: surface reactive carbohydrates detected by lectin probes. Exp Parasitol 1988; 67: 137-47.
28. Lundgren B, Lipschik GY, Kovacs JA. Purification and characterization of a major human *Pneumocystis carinii* surface antigen. J Clin Invest 1991; 87: 163-70.
29. Pottratz ST, Paulsrud J, Smith JS, Martinil WJ. *Pneumocystis carinii* attachment to cultured lung cells by *Pneumocystis* gp120, a fibronectin binding protein. J Clin Invest 1991; 88: 403-7.
30. Craig L, Franklin K, Lela K, Riley. *Pneumocystis carinii*: History, Classification, Clinical disease, Pathology, Diagnosis and control in laboratory animals. Available at: www.criver.com Assessed July 30, 2004.
31. Sidhu GS, Cassai ND, Pei Z. *Pneumocystis carinii*: An update. Ultra Patho 2003; 27: 115-22.
32. Hughes WT, Bartley DL, Smith BM. A natural source of infection due to *Pneumocystis carinii*. J Infect Dis 1983; 147: 595.
33. Pifer LL, Hughes WT, Stagno S, Woods D. *Pneumocystis carinii* infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61: 35-41.
34. Wakefield AE, Stewart TJ, Moxon ER, Marsh K, Hopkin JM. Infection with *Pneumocystis carinii* is prevalent in healthy Gambian children. Trans R Soc Trop Med Hyg 1990; 84: 800-2.
35. Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera CE, Cumsille F, Gigliotti F. Search for primary infection by *Pneumocystis carinii* in a cohort of normal, healthy infants. Clin infect Dis 2001; 32: 855-61.
36. Smulian AG, Keely SP, Sunkin SM, Stringer JR. Genetic and antigenic variation in *Pneumocystis carinii* organisms: tools for examining the epidemiology and pathogenesis of infection 1997; 130: 461-8.
37. Wakefield AE, Pixley FJ, Banerji S, Sinclair K, Miller RF, et al. Detection of *Pneumocystis carinii* with DNA amplification. Lancet 1990; 336: 451-3.
38. Peter SE, Wakefield AE, Sinclair K, Miller RF, et al. A search for *Pneumocystis carinii* in post-mortem lungs by DNA amplification. J Pathol 1992; 166: 195-8.
39. Morris A, Beard CB, Laurence H. Update on the epidemiology and transmission of *Pneumocystis carinii*. Micr Infect 2002; 4: 95-103.
40. Keely SP, Stringer JR, Baughman RP, Linke MJ, et al. Genetic variation among *Pneumocystis carinii* hominis isolates in recurrent pneumocystosis. J Infect Dis 1995; 172: 595-8.
41. Keely SP, Baughman RP, Smulian AG. Source of *Pneumocystis carinii* in recurrent episodes of pneumonia in AIDS patients. AIDS 1996; 10: 881-8.
42. Lee CH, Lu JJ, Tang X, Jiang B, Li B, et al. Prevalence of various *Pneumocystis carinii* sp. hominis types in different geographical locations. J Eukaryot Microbiol 1996; 43: S37.
43. Beard CB, Carter JL, Keely SP, Huang L, et al. Genetic variation in *Pneumocystis carinii* isolates from different geographic regions: implications for transmission. Emerg Inf Dis 2000; 6: 265-72.
44. Helweg-Larsen J, Tsolaki AG, Miller RF, Lundgren B, et al. Cluster of *Pneumocystis carinii* pneumonia: analysis of person-to-person transmission by genotyping. Q L Med 1998; 91: 813-20.
45. Latouche S, Poirot JL, Maury E, Bertrand V, et al. *Pneumocystis carinii* sp. hominis sequencing to study hypothetical person-to-person transmission. AIDS 1997; 11: 549.
46. Maxfield RA, Sorkin IB, Fazzini, EP. Respiratory failure in patients with the acquired immunodeficiency syndrome and *Pneumocystis carinii* pneumonia. Critical Care Medicine 1986; 14: 443-9.
47. Peters SG, Prakash. Pneumocystis pneumonia: review of 53 cases. American Journal of Medicine 1985; 82: 73-8.
48. Kovacs JA, Hiemenz JW, Macher AM. *Pneumocystis carinii* pneumonia. A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100: 663-71.
49. Opravil M, Marincek B, Fushs WA. Short-comings of chest radiography in detecting *Pneumocystis carinii* pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 1994; 7: 39-45.
50. Suffredini AF, Ognibene FP, Lack EE. Nonspecific interstitial pneumonitis: a common cause of pulmonary disease in the Acquired Immunodeficiency syndrome. Annals of Internal Medicine 1987; 107: 7-13.
51. Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 1996; 124: 585-99.

52. Torrington KG, Finelli MR. Small volume bronchoalveolar lavage used in diagnosing *Pneumocystis carinii* pneumonia in HIV-infected patients. *Chest* 1995; 107: 1013-7.
53. Wilai S, Boonchay E, Rosarin C, Ratchadaporn C. Comparison of methods for identification of *Pneumocystis carinii* in Bronchoalveolar lavage fluid. *J Med Assoc Thai* 2002; 85 (suppl 1): S407-14.
54. Kim YK, Parulekar S, Yu PKW, Pisani RJ, Smith TF, Anhalt JP. Evaluation of calcofluor white stain for detection of *Pneumocystis carinii*. *Diagn Microbiol Infect Dis* 1990; 13: 307-10.
55. Kovacs JA, Gill V, Swan JC, et al. Prospective evaluation of a monoclonal antibody in diagnosis of *Pneumocystis carinii* pneumonia. *Lancet* 1986; 2: 1-3.
56. Wakefield AE, Pixley FJ, Banerji S, Sinclair K, Miller RF, Moxon ER, et al. Detection of *Pneumocystis carinii* with DNA amplification. *Lancet* 1990; 336: 452-3.
57. Tamburrini E, Mencarini P, Visconti E, et al. Detection of *Pneumocystis carinii* DNA in blood by PCR is not of value for diagnosis of *Pneumocystis carinii* pneumonia. *J Clin Microbiol* 1996; 34: 1586-8.
58. The therapeutic guidelines for the treatment of HIV/AIDS and related condition. Available at [www.hivnet.ubc.ca](http://www.hivnet.ubc.ca) Assessed July19, 2004.
59. The National Institute of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for pneumocystis pneumonia. Consensus statement on the use of corticosteroid as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. *N Engl J Med* 1990; 323: 1500-4.
60. Charles F, Thomas Jr, Andrew HL. *Pneumocystis pneumonia*. *New Eng J Med* 2004; 350: 2487-98.
61. Masur H, Kaplan JE, Holmes KK. Guideline for preventing opportunistic infections among HIV-infected persons-2002: recommendations of the US Public Health Service and the Infectious Disease Society of America. *Ann Intern Med* 2002; 137: 435-78.
62. Yale SH, Limper AH. *P. carinii* pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. *Mayo Clin Proc* 1996; 71: 5-13.
63. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected *P. carinii* pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. *AJR Am J Roentgenol* 1997; 169: 967-75.
64. Jannik Helweg-Larsen, Thomas L Benfield, Jesper Eugen-Olsen, Jens D Lundgren, Bettina Lundgren. Effects of mutations in *Pneumocystis carinii* dihydropteroate synthase gene on outcome of AIDS-associated *P. carinii* pneumonia. *Lancet* 1999; 354: 1347-51.
65. Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of cotrimaxazole *Pneumocystis carinii* infection and mutations in dihydropteroate synthase gene. *Lancet* 1998; 351: 1347-51.
66. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *MMWR Morb Mortal Wkly Rep* 1999; 48: 1-66.
67. Fungal genome initiative. Available at [www.genome.wi.mit.edu/annotation/fungi/fgi](http://www.genome.wi.mit.edu/annotation/fungi/fgi) Assessed Jul 20, 2004.

---

## โรคปอดอักเสบจากเชื้อ *Pneumocystis* sp.: ล่าสุด

สุริยพร ศรีตั้งรัตนกุล, สุรางค์ นุชประยูร, อิศรางค์ นุชประยูร

โรคปอดอักเสบจากเชื้อ *Pneumocystis* sp. เป็นสาเหตุของการป่วยและการเสียชีวิตที่สำคัญในผู้ป่วยที่มีภูมิคุ้มกันโรคต่ำ ผู้ป่วยโรคปอดอักเสบจากเชื้อ *Pneumocystis* sp. ในประเทศไทยมีจำนวนเพิ่มทุกปีตั้งแต่ปี 2535 ถึง ปี 2545 และมีจำนวนผู้ป่วยสูงสุดถึง 6,255 คนในปี 2545 เชื้อ *Pneumocystis* sp. ที่ก่อให้เกิดโรคในคน คือ *Pneumocystis jirovecii* *Pneumocystis* sp. ถูกค้นพบเป็นเวลานานเกือบศตวรรษ แต่มีความรู้ความเข้าใจเกี่ยวกับเชื้อนี้น้อย จนกระทั่งมีการใช้เทคนิคทางชีวภาพโมเลกุลช่วยให้นักวิทยาศาสตร์มีความเข้าใจธรรมชาติของเชื้อราในอดีต *Pneumocystis* sp. ถูกจัดให้เป็นพวกโปรโตซัวเนื่องจากรูปร่างของเชื้อ ในเวลาต่อมา *Pneumocystis* sp. ถูกจัดให้เป็นพวกรา เนื่องมาจากการวิเคราะห์ทาง DNA ยาโคไทรโมซอลเป็นยาที่มีส่วนผสมของตัวยาไตรเมโทพริม และ ซัลฟาเมทอซอล ยาตัวนี้เป็นยาชนิดแรกที่เลือก ให้อำนาจและรักษาโรคปอดอักเสบจากเชื้อ *Pneumocystis* sp. มีหลักฐานเพิ่มมากขึ้นเกี่ยวกับการกลายพันธุ์ที่ตำแหน่งของเอ็นไซม์ ไดไฮดรอพเทอโรเลท ซินเทส (ดีเอชพีเอส) ซึ่งเป็นตำแหน่งเป้าหมายของยา sulfas ทำให้มีการดื้อต่อยา sulfas

---